265: Novavax's CEO promises a turnaround & how Lilly roiled the obesity market
The Readout Loud
00:00
The Future of Obesity Drugs
Lilly's wagovi showed about 15% weight loss in a Phase 2 trial. Novo also had data on an oral drug, the kind of oral version of wagovi. And that was also about 15%. The difference between Lilly and Novo's oral products is Lilly's is a small molecule; Novo's is an oral peptide.
Transcript
Play full episode
